Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Almost all patients with oral corticosteroid (OCS)-dependent severe, uncontrolled asthma achieved a maintenance OCS dose of 5 mg per day or less and more than half completely discontinued OCS while maintaining asthma control after 52 weeks of…